Budget 2023Budget 2023


  • Tata AIA Life Insurance
  • Hafele
  • Motilal Oswal
Live: Budget 2023: Will India Spend More?
Budget 2023
Budget 2023

Buy Sanofi India: target of Rs 9250: Sharekhan

Sharekhan is bullish on Sanofi India has recommended buy rating on the stock with a target price of Rs 9250 in its research report dated February 23, 2022.

February 24, 2022 / 12:17 PM IST
  • bselive
  • nselive
Todays L/H

Sharekhan's research report on Sanofi India

Sanofi reported weak performance for quarter and results missed estimates. Although numbers are not comparable on a y-o-y basis due to the hiving off of the neutraceuticals business. Revenues and adjusted PAT declined by 4.5% and 26.5% yoy respectively. Divesture of Nutraceuticals business as well as slow moving brands, to remove a drag on the company’s growth and would facilitate enhanced focus on key growth areas – anti diabetes, cardiac.. High-growth visibility from chronics, strong, debt-free balance sheet, sturdy dividends and healthy cash position are the key positives.


We retain Buy recommendation on Sanofi India Limited (Sanofi) with a revised PT of RS 9250.